Biotech Firm GeoVax Labs To Phase II trials of HIV Vaccine Candidate startingThe Atlanta-based biotechnology company GeoVax Labs plans to phase II clinical trial of its experimental HIV vaccine this summer, company officials announced recently that Atlanta Journal-Constitution reports (Hendrick, Atlanta Journal-Constitution.

Into Phase III. There are still a number of hurdles to overcome. .. Mitchell Warren, managing director of the AIDS Vaccine Advocacy Coalition, said the rise vaccine in phase II studies is a significant achievement. GeoVax phase I data is compelling and Garan[t] recording in Phase II, he said, But there is still much more to do, Warren said, adding:. They are not on the search for efficacy in these studies. That comes later in much larger studies.Information is from by courtesy from the Henry J. Kaiser Family Foundation. She can view the entire Kaiser Daily Global Health policy coverage looking browsing the archives and log in for email for delivery to global health.